✦ LIBER ✦

Estrogen replacement therapy withdrawal and regression of metastatic breast cancer

✍ Scribed by Madhav V. Dhodapkar; James N. Ingle; David L Ahmann

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 353 KB
Volume: 75
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950101)75:1<43::aid-cncr2820750109>3.0.co;2-#

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Menopausal estrogen replacement therapy

Menopausal estrogen replacement therapy in women with breast cancer

✍ Kathleen I. Pritchard; Carol A. Sawka 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB 👁 1 views

Replacement estrogens and risk of gyneco

Replacement estrogens and risk of gynecologic cancers and breast cancer

✍ Barbara S. Hulka 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 491 KB 👁 1 views

Rebound response after estrogen therapy

Rebound response after estrogen therapy for metastatic breast cancer

✍ Richard W. Nesto; Blake Cady; Richard A. Oberfield; Artemis G. Pazianos; Ferdina 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 1 views

Estrogen replacement therapy for the bre

Estrogen replacement therapy for the breast cancer survivor: A reappraisal

✍ Disaia, Philip J. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

Metastatic breast cancer in males assess

Metastatic breast cancer in males assessment of endocrine therapy

✍ Jashbhai K. Patel; Takuma Nemoto; Thomas L. Dao 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB 👁 2 views

22 men with metastatic breast cancer were treated with endocrine therapy. All 22 patients were initially treated by bilateral orchiectomy, and objective response was seen in 11 (50%) patients for 15 months. Bilateral adrenalectomy was performed subsequently in 10 patients, and 8 (80%) patients had a

Estrogen replacement therapy in women wi

Estrogen replacement therapy in women with a history of proliferative breast disease

✍ William D. Dupont; David L. Page; Fritz F. Parl; W. Dale Plummer Jr.; Peggy A. S 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

Dr. Dupont has accepted honoraria for presenting papers at professional meetings from pharmaceutical firms that market hormonal replacement therapy. On three occasions in his career he has been a consultant for Wyeth-Ayerst Pharmaceuticals. The authors thank Marcia G. Freudenthal, Cheryl D. Sharpe,